Skip to main content

Table 3 Eradication rates per protocol in peptic ulcer disease and dyspepsia in groups of active and placebo probiotic

From: Association of a probiotic to a Helicobacter pylorieradication regimen does not increase efficacy or decreases the adverse effects of the treatment: a prospective, randomized, double-blind, placebo-controlled study

 

Peptic ulcer (CI 95%)

Dyspepsia (CI 95%)

Active probiotic

95.8% (87-100%)

84.0% (74-100%)

Placebo probiotic

85.7% (69-100%)

84.6% (70-99%)

Pearson Chi-Square

p = 0.23

p = 0.95